News Analysis This is the second of three articles that introduce readers to the research and mission of BGI Group, China’s leading genome sequencing company with customers around the globe. Its research involves collecting, studying, and altering human and animal genes to facilitate such things as biochemical weapons development and even customizing humans. The BGI Annual Report for 2020 says it is committed to promoting China’s globalization efforts and supports the Chinese Communist Party’s (CCP) “One Belt, One Road” strategy. The report shows how BGI expanded its operations across China, opened gene banks and research facilities in Xingjiang and Tibet, and is now serving customers in more than 100 countries. The CCP strategy of a “Healthy China” has enabled BGI to conduct large-scale screening and acquire biomedical data on Chinese people. The accumulated data expedites their work in building a national network of gene banks and research bases targeting Chinese …